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Locally advanced breast cancers (LABCs) are characterized by tumors larger than 5 cm; the presence of fixed axillary lymph nodes;  positive ipsilateral supraclavicular, infraclavicu-lar, or internal mammary nodes; skin ulceration; dermal infiltration; erythema or “peau d’orange”; 
tumor fixation to the ribs or muscles; and inflam-
matory carcinomas.1
The oncological treatment of LABC is well estab-
lished; however, the safety and the efficacy of imme-
diate reconstruction in this group of patients remain 
unknown.2–4 Radiotherapy is typically indicated for 
these patients, and the effects of such treatment on 
breast reconstruction are the subject of ongoing de-
bate.5–13 Moreover, the type and the timing of recon-
struction for LABC patients continue to be points 
of major controversy.2–4,14 These patients are consid-
ered difficult candidates for reconstruction because 
of the significantly greater risk of local recurrence, 
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Background: Recent papers and guidelines agree that patients with locally ad-
vanced breast cancer (LABC) should be offered breast reconstruction. Yet, the 
type of reconstruction in this group of patients is still a point of controversy.
Methods: One hundred fourteen patients, treated for LABC from 2007 to 
2013, were divided into 3 groups based on the reconstructive option: no re-
construction (NR), implant-based/expander-based reconstruction (IBR), and 
autologous tissue reconstruction (ATR). We analyzed demographics and com-
pared delay in adjuvant therapy, length of hospitalization, surgical complica-
tions, failure of reconstruction, local recurrence, and disease-free survival.
Results: Twenty-six patients had NR, 38 had IBR, and 50 had ATR. No signifi-
cant difference was found in the percentage of patients who had their adjuvant 
treatment delayed [16% (NR) vs 22% (IBR) vs 14% (ATR)]. Mean length of 
hospitalization for the NR, IBR, and ATR groups was 2.7, 6, and 7.5 days, respec-
tively. Complication rates requiring readmission were 36% (NR), 42% (IBR), 
and 32% (ATR). In the IBR group, 37% of implants were removed because 
of complications. Failure of reconstruction was 37% and 0% for the IBR and 
ATR groups, respectively. Local recurrence rates in the NR and Reconstruction 
(groups IBR and ATR combined) groups were 7% and 2%, respectively. Mean 
survival times in patients were 18 (NR), 10.3 (IBR), and 12.2 (ATR) months.
Conclusions: No significant difference was found in the hospital stay length, 
adjuvant treatment delay, and complication rates between IBR and ATR. 
High rates of failed reconstruction suggest that the use of implants should 
be considered very carefully in patients with LABC. (Plast  Reconstr Surg Glob 
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more aggressive adjuvant and neoadjuvant treat-
ments, and reduced survival.
Currently, the incidence of locally advanced can-
cer is lower than it has been because of improved 
diagnostic techniques and greater public awareness 
of breast cancer.15 However, 3% to 5% of all of the 
breast cancer cases and 3000 to 5000 cases per annum 
in the United Kingdom present as locally advanced 
disease. Among the locally advanced population, we 
have observed that patients request reconstruction 
despite knowing that their mortality prognosis might 
not be favorable. Oncologically safe reconstruction 
with low complication rates is a high priority for this 
group of patients.
The number of currently available comparative 
studies of patients with LABC is limited, and the 
outcomes are controversial2,14,16–23 (Table 1). The 
purposes of this study were to provide an objective 
analysis of the outcomes of different types of recon-
struction based on a large cohort of patients with 
LABC who were treated in a single centre and to 
compare implant-/expander-based reconstruction 
(IBR), autologous tissue reconstruction (ATR), and 
control no reconstruction (NR) groups.
METHODS
Patient	Groups
A retrospective evaluation was performed for 
all patients with LABC who underwent surgery 
with or without immediate reconstruction at St. 
Thomas’s Hospital, London, United Kingdom 
from February 2007 to April 2013. We compared 3 
groups: NR group, IBR, to reflect a relatively quick 
and simple reconstructive technique with no do-
nor site that involves the use of implant materials, 
and a group with ATR, reflecting a more complex 
reconstructive technique with a donor tissue site 
that brings in nonirradiated tissue and does not 
involve the use of implants. The data were col-
lected from the case notes and included patient 
demographics, length of hospital stay, median 
follow-up time, delays in adjuvant therapy, surgi-
cal complications, failure of reconstruction, local 
recurrence, and survival.
Statistical	Methods
The statistical analyses were performed using 
SPSS Statistics version 20. Pearson’s χ2 tests were 
used for analyses of survival, delays in adjuvant treat-
ment, and complications. Mann-Whitney and Krus-
kal Wallis tests were used to evaluate the length of 
hospital stay, and Student’s t test was used to exam-
ine age and tumor size. Statistical significance was 
taken at P < 0.05. Ta
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RESULTS
Patient	Demographics
Of the 114 identified patients, 50 patients under-
went ATR with a deep inferior epigastric perforator, 
transverse rectus abdominis myocutaneous, or latis-
simus dorsi flaps; 38 patients underwent reconstruc-
tion with implants or expanders; and 26 patients 
underwent NR. The patients’ demographic data are 
presented in Table 2.
The median ages were 48 (29–75) years in the IBR 
group, 50 (25–70) years in the ATR group, and 54 
(24–77) years in the NR group. The patients who un-
derwent reconstruction were slightly younger than 
the nonreconstructed patients (Table 2). The ATR 
group tended to have larger tumors than the IBR 
group (71.7 vs 62.1 mm in mean size). The NR group 
had an average tumor size of 62.7 mm, although this 
was not significantly different from the mean tumor 
size of the patients who underwent reconstruction 
(ie, the R group; Table 3). The patients with chest 
wall involvement were less likely to undergo recon-
struction. Only 6 of 13 patients with chest wall in-
volvement underwent reconstruction compared with 
82 of 101 patients with no chest wall involvement. All 
22 patients with no axillary node involvement under-
went reconstruction, whereas 66 of 92 patients with 
nodal involvement did so (P = 0.002). Among the 
89 patients with no evidence of metastasis, 74 pa-
tients underwent reconstruction. Of the 24 patients 
who had distant metastases, 14 patients underwent 
reconstruction based on the multidisciplinary treat-
ment recommendation and patients’ preference.
Delay	in	Adjuvant	Therapy
Seventy-one patients received neoadjuvant che-
motherapy, and 24 patients received adjuvant che-
motherapy. Eighty-six of 114 patients had adjuvant 
radiotherapy with no significant difference between 
the reconstruction groups and NR group (69% in 
the IBR group and 68% in the ATR group vs 71% 
in the NR group). A delay in adjuvant therapy was 
defined as a delay of 4 or more weeks. No signifi-
cant differences were found in the percentages of 
patients who had their adjuvant treatment delayed 
(chemotherapy or radiotherapy) between the differ-
ent groups (16% in the NR vs 18% in the Recon-
struction (groups IBR and ATR combined) group (R 
group); 22% in the IBR vs 14% in the ATR groups).
Length	of	Hospital	Stay
The median length of hospitalization for the NR, 
IBR, and ATR groups was 2, 6, and 7.5 days, respec-
tively (Table 4). As expected, there were significant 
differences between the length of the hospital stay of 
the R and NR groups (P < 0.001) and between those 
of the IBR and ATR groups (P = 0.006).
Medial	Follow-up	Time
The median follow-up time for the IBR, ATR, and 
NR groups was 28.2, 27.8, and 26.1 months, respec-
tively (Table 4).
Complications
The rates of complications that required readmis-
sion were 42% and 32% in the IBR and ATR groups, 
respectively (Table 4). As expected, the frequency of 
major complications was higher among the reconstruct-
ed patients than the nonreconstructed patients (36% vs 
8% P = 0.006). In the IBR group, 37% of the implants 
were removed because of acute or late complications.
Failure	of	Reconstruction
In the IBR group, 37% of the implants had to 
be removed because of early or late complications, 
whereas in the ATR group, there was no complica-
tion of flap failure (Table 4). There was a significant 
difference in the rate of failure of the reconstruc-
tion, 37% versus 0% (P = 0.001).
Survival	and	Local	Recurrence
At a mean follow-up time of 28 months, the local 
recurrence rates in the NR and R groups were 7% 
and 2%, respectively (Table 4). Among the recon-
structed patients, the local recurrence rates were 4% 
in the ATR group and 0% in the IBR group. At the 
Table 2. Patient Demographics
Age (y)
  Mean 50.6
  Range 24–77
Tumor size (mm)
  Mean 66.5
  Range 10–140
Site (n)
  Left 50
  Right 64
Surrounding involvement (n)
  Skin 69
  Chest wall 13
  Axillary nodes 92
  Other nodes 25
Distant metastasis (n)
  Yes 24
  No 89
Oncological therapy (n)
  Neoadjuvant chemotherapy 71
  Adjuvant chemotherapy 24
  Adjuvant radiotherapy 82
Reconstruction (n)
  Yes 88
  No 26
Survival (mo)
  Mean 33
  Range 7–147
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time of the completion of the study, 27% of the NR 
patients and 12.5% of the R patients had died. The 
median survival times of the deceased patients were 
21, 10.5, and 11.5 months in the NR (n = 7), IBR 
(n = 4), and ATR (n = 6) groups, respectively.
DISCUSSION
Reconstruction in LABC requires a very cautious 
and individual approach. Guidelines advise that re-
construction should be offered to all breast cancer 
patients. Opinions regarding the timing and types 
of reconstruction can vary substantially among sur-
geons, particularly in cases of advanced disease.24 
Important factors, such as disease progression and 
response to neoadjuvant treatment, need to be taken 
into consideration, especially the effect of radiother-
apy. Authors like Cordeiro and Nava have supported 
the use of implants for breast reconstruction; how-
ever, they acknowledge the higher failure rates and 
capsular contracture in patients who have had radio-
therapy.9,10 Our study supports the benefits of autolo-
gous breast reconstruction over IBR in LABC.
Skin-sparing mastectomy followed by immediate 
reconstruction provides the best aesthetic outcome; 
studies supporting the use of skin-sparing mastecto-
my for LABC patients are uncommon, and the ma-
jority of such reports are limited to relatively small 
groups of patients.16,25–27 In our series, skin-sparing 
mastectomy was offered to all patients with (nonin-
flammatory) locally advanced cancer with no skin 
involvement regardless of cancer stage. We ensured 
that the skin incisions were well clear of any disease 
and that there was a clear plane between the most 
superficial tumor and overlying skin.  Adjuvant post-
Table 3. Comparisons of Age, Tumor Size, Distant Metastasis, and Chest Wall, Axillary, and Distant Nodal 
Involvement Among the 3 Groups (NR, IBR, and ATR Groups)
NR	(n	=	26) IBR	(n	=	38) ATR	(n	=	50)
P
NR	vs	Reconstruction IBR	vs	ATR
Age (y)
  Median (range) 54 (24–77) 48 (29–75) 50 (25–70) ns ns
Tumor size (mm)
  Mean (range) 62.7 (51.1–74.4) 62.1 (56.7–67.5) 71.1 (64.5–79.0) ns ns
Chest wall involvement
  No (n = 101) 19 37 45 0.005 ns
  Yes (n = 13) 7 1 5
Axillary nodes involvement
  No (n = 22) 0 7 15 0.002 ns
  Yes (n = 92) 26 31 35
Distant nodes involvement
  No (n = 89) 14 32 43 0.005 ns
  Yes (n = 25) 12 6 7
Distant metastasis
  No (n = 89) 15 31 43 0.009 ns
  Yes (n = 24) 10 7 7
ns, not significant.
Table 4. Comparisons of the Length of Hospital Stay, Median Follow-up Time, Failure of Reconstruction, Major 
and Minor Complications, Local Recurrence, and Survival Time Among the 3 Groups (NR, IBR, and ATR Groups)
NR	(n	=	26) IBR	(n	=	38) ATR	(n	=	50)
P
NR	to	Reconstruction IBR	to	ATR
Length of hospital stay (d)
  Median (range) 2 (1–14) 6 (1–18) 7.5 (3–25) 0.001 0.006
Median follow-up time (mo) 26.1 28.2 27.8
Failure of reconstruction — 14 0 0.001
Complications (% of cases)
  Major* 8 42 32 0.006 ns
  Minor† 36 53 54 ns ns
Local recurrence‡ (n) 3 0 1
Survival time of those who died (mo)
  Median (range) n = 7
21 (8–29)
n = 4
10.5 (6–14)
n = 6
11.5 (3–25)
ns ns
*Major complications, such as infection, requiring readmission or events leading to reoperation (eg, hematoma, seroma, microsurgery com-
plications, implant infection).
†Minor complications, such as superficial wound infection at surgical site, which did not required readmission.
‡The mean follow-up time was 28 mo.
ns, not significant.
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mastectomy  radiotherapy is indicated for the follow-
ing conditions: tumors larger than 4 cm, tumors with 
close or positive margins at mastectomy, the presence 
of more than 3 positive axillary lymph nodes, and cas-
es of local recurrence.28 Factors such as tumor grade 
are also taken into consideration. According to our 
protocol, all patients with LABC received postopera-
tive radiotherapy; however, some of the patients in 
our group had previously received radiotherapy af-
ter previous wide local excisions. The effects of re-
construction on the delivery of radiotherapy remain 
a worrisome issue; however, no delays in delivery of 
adjuvant radiotherapy were found. We studied the 
outcomes of breast reconstruction offered to the 
patients dividing them into a group of patients who 
had IBR and a group of patients who had ATR. We 
acknowledge that our ATR group is relatively het-
erogeneous, including DIEPs, superior gluteal artery 
perforators, transverse rectus abdominis myocutane-
ous, and latissimus dorsi reconstructions; however, all 
of these reconstructions have in common that they 
bring in fresh nonirradiated tissue, are relatively long 
operations (usually >4 hours), and have donor sites, 
with the potential for additional morbidity while they 
do not need the use of implant materials, with their 
associated complications.
Most studies of the delay in adjuvant treatment af-
ter immediate reconstruction have described short-
time delays or no delays in the start of chemotherapy 
after reconstruction. There is no evidence related to 
the oncologic repercussions of the 1- or 2-week de-
lays that can be caused by surgical complications.29 
In our study, the NR group exhibited a rate of delay 
in adjuvant treatment (chemotherapy or radiother-
apy) that was nearly identical to that of the R group.
Immediate, delayed-immediate, and delayed 
reconstructions have each been considered to be 
the preferred option for patients with LABC by dif-
ferent authors. It has been shown that immediate 
reconstruction does not compromise survival or re-
currence rates at any stage of breast cancer.2,4,17,24,30 
Neoadjuvant chemotherapy and adjuvant radio-
therapy are indicated for most LABC patients. 
These procedures might increase the risk of surgical 
complications. Baumann et al20 provided evidence 
that the optimal timing for delayed ATR should be 
12 months after the completion of radiotherapy. 
However, in situations of high-risk cancers and 
potentially short life expectancies, many women do 
not wish to wait for a delayed reconstruction.
As expected, the rate of major complications was 
higher in our R patients than in our NR patients. 
The difference in major complications between the 
ATR and the IBR groups was not statistically signifi-
cant, but this rate was higher in the implant group. 
The 6-day median hospital stay of the IBR groups 
was unexpectedly high. This reflects the practice at 
the time of keeping patients in hospital until drain 
removal. Usual practice is now to discharge patients 
home with drains in situ, and so hospital stay for 
IBR is usually 24 to 48 hours. The incidence of loss 
of implants and expanders we observed in patients 
with LABC was 37%, which is similar to the findings 
of other studies.14,31 This rate is significantly higher 
than the implant loss rates of non-LABC patients9,10; 
the failure of reconstruction was significantly higher 
in the IBR compared with the ATR group, as no flaps 
failed opposed to the 37% of implants that had to 
be removed. Therefore, the use of IBRs for LABC 
patients should be considered very carefully.
Why is expander loss so detrimental to further 
ATR? The majority of the losses of expanders and 
implants that we observed were caused by recurrent 
infections.31 Infection causes inflammation and scar-
ring, and it delays any further reconstruction. Con-
sidering the poorer survival prognoses of the patients 
with LABC, many of these women might ultimately 
not only lose their expander but also be without any 
reconstruction at all. The inflammation and capsule 
formation caused by expanders in cases of delayed-
immediate reconstruction make the preparation of 
the recipient sites for flaps more technically diffi-
cult.2 The methods that have been proposed to re-
duce implant loss after radiotherapy include partial 
deflation of the expander during the period of ra-
diotherapy, extension of the pocket, and meticulous 
drain management; thus, this issue remains an im-
portant area for future research.14
The high rate of expander loss observed in the 
LABC patients, as experienced in our unit, supports 
the use of ATR for patients who are undergoing 
chemotherapy and adjuvant radiotherapy because 
this type of reconstruction is potentially less risky 
and more cost-effective than IBR, leading to signifi-
cantly higher rate of successful reconstruction. In 
addition, the patient satisfaction rates with recon-
struction in settings of radiotherapy have been re-
ported to be significantly higher for ATR than for 
IBR.11,12 However, with careful patient selection, 
other authors have reported a relatively lower rate 
of failure of IBR.9,10 Identifying the optimal recon-
structive method for each individual patient is an 
important skill and priority, particularly for patients 
with LABC.
CONCLUSIONS
Postmastectomy reconstruction is important and 
should be considered for all patients with LABC. 
Patients must be adequately informed of the risks, 
complications, and potential long-term cosmetic 
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outcomes. The potential superiority of ATR over IBR 
observed in our series should be noted.
Grigorios Tanos, MD
Department of Plastic Surgery
Southmead Hospital
North Bristol NHS Foundation, Trust
Bristol, United Kingdom
E-mail: greg.tanos@gmail.com
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